Using phosphorylation signatures of drug perturbagens to identify exercise-mimetic compounds
Project Number1R03OD032626-01
Former Number1R03DE031357-01
Contact PI/Project LeaderMANI, DENKANIKOTA R
Awardee OrganizationBROAD INSTITUTE, INC.
Description
Abstract Text
Project Summary
Protein phosphorylation plays a major role in perturbation-induced signal transduction. The Library of Integrated
Network-based Signatures (LINCS) P100 project has generated targeted (using 96 carefully chosen
phosphosites) and comprehensive (using DIA, data independent acquisition) mass spectrometry (MS)-based
phosphoproteomic datasets characterizing cell states perturbed using a collection of common bioactive
therapeutic (“known”) compounds. The analysis of phosphoproteomics data acquired using DIA is challenging,
and as a result the comprehensive LINCS DIA data has not yet been leveraged to its full potential. The Molecular
Transducers of Physical Activity (MoTrPAC) consortium has also used phosphoproteomics (along with other
omics data) to quantify the molecular effects of exercise. Using methods like post-translational modification site-
specific enrichment analysis (PTM-SEA, Krug et al. MCP, 2019), perturbation-induced phosphorylation
signatures can be correlated with exercise-induced phosphorylation changes to identify known compounds that
can mimic the effects of physical activity, providing an exciting opportunity to enhance the combined utility and
impact of the LINCS and MoTrPAC Common Fund datasets.
The goal of our proposal is to test the hypothesis that there are known compounds that can mimic the effects of
physical activity. To accomplish this goal, the PTM signatures database (PTMsigDB) will be significantly
expanded using the LINCS DIA data.These signatures will then be correlated with phosphoproteomic changes
induced by physical activity provided by MoTrPAC to nominate exercise-mimetic drugs.
With these goals in mind we will 1) Develop and apply an automated, cloud-based pipeline to greatly expand
phospho-perturbation profiles from existing LINCS data from 100 to several thousand distinct phosphosites; 2)
Derive perturbation-specific phosphoproteomic signatures from the greatly expanded phospho-profiling data;
and 3) Identify exercise mimetic drugs using PTM signature enrichment in MoTrPAC phosphoproteomic data
from acute and long-term exercise. Successful application of the proposed strategy will nominate a list of
exercise-mimetic drugs with the potential to initiate entirely new avenues of research focused on finding new
therapeutic approaches to combat aging or muscle wasting (cachexia) in cancer patients.
Public Health Relevance Statement
Project Narrative:
Repurposing of existing drugs to treat diseases outside the scope of the original medical indication is increasingly
being explored. Our proposal attempts to identify therapeutic compounds (drugs) that could mimic the effects of
physical activity. Successful application of the proposed strategy has the potential to initiate entirely new avenues
of research aimed at finding new therapeutic approaches to combat aging or muscle wasting (cachexia) in cancer
patients.
No Sub Projects information available for 1R03OD032626-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03OD032626-01
Patents
No Patents information available for 1R03OD032626-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03OD032626-01
Clinical Studies
No Clinical Studies information available for 1R03OD032626-01
News and More
Related News Releases
No news release information available for 1R03OD032626-01
History
No Historical information available for 1R03OD032626-01
Similar Projects
No Similar Projects information available for 1R03OD032626-01